Drug news
NICE rejects Xalkori for NHS use in ROS-1 positive non-small cell lung cancer.- Pfizer.
In draft guidance, the National Institute for Health and Care Excellence (NICE) has not recommended Xalkori (crizotinib), from Pfizer, for routine NHS use in ROS1 positive advanced non-small cell lung cancer patients. NICE doesn�t recommend Xalkori for patients previously treated as its cost-effectiveness estimates are beyond what it normally considers acceptable for therapies deemed �end-of-life� treatments. NICE will take public comments until Feb. 7, ahead of a second appraisal meeting on Feb. 21.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.